SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS WEE1 INHIBITORS

1 . A compound of Formula (I):

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

Y is hydrogen or R 4 ;

m is 0, 1, 2, or 3;

n is 0, 1, 2, 3, or 4;

R 1 is independently F, Cl, or methyl;

R 2 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl or —(C 1 -C 3 alkylene)CF 3 ;

R 3 is

 wherein:

 indicates an aromatic ring;

M 1 is CH or CR 3 ;

M 2 is CH, CR 3b , N, or absent;

M 3 is CH, CR 3b , N, O, or S;

M 4 is CH, CR 3 b, N, O, or S,

provided that:

(1) when M 4 is O or S and M 2 is absent, then M 3 is CH, CR 3b or N, and

(2) when M 3 is O or S and M 2 is absent, then M 4 is CH, CR 3b or N;

R 3a is C 3 -C 6 cycloalkyl optionally substituted by C 1 -C 6 haloalkyl or —CN, or C 1 -C 6 alkyl optionally substituted by halogen, —OH or —CN, provided that when R 3a is C 1 -C 6 alkyl optionally substituted by halogen, —OH or —CN, then at least one of M 1 , M 2 , M 3 , and M 4 is CR 3b ;

R 3b is halogen or —CN;

each R 4 is independently oxo, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, halogen, —C(O)R 17 , —C(O)OR 17 , —C(O)NR 17 R 18 , —CN, —Si(C 1 -C 6 alkyl) 3 , —OR 17 , —NR 17 R 18 , —OC(O)NR 17 R 18 , —NR 17 C(O)R 18 , —S(O) 2 R 17 , —NR 17 S(O) 2 R 18 , —S(O) 2 NR 17 R 18 , C 3 -C 6 cycloalkyl, 3- to 6-membered heterocyclyl, —(C 1 -C 3 alkylene)CN, —(C 1 -C 3 alkylene)OR 17 , —(C 1 -C 3 alkylene)NR 17 R 18 , —(C 1 -C 3 alkylene)CF 3 , —(C 1 -C 3 alkylene)C(O)R 17 , —(C 1 -C 3 alkylene)C(O)NR 17 R 18 , —(C 1 -C 3 alkylene)NR 17 C(O)R 18 , —(C 1 -C 3 alkylene)S(O) 2 R 17 , —(C 1 -C 3 alkylene)NR 17 S(O) 2 R 18 , —(C 1 -C 3 alkylene)S(O) 2 NR 17 R 18 , —(C 1 -C 3 alkylene)(C 3 -C 6 cycloalkyl) or —(C 1 -C 3 alkylene)(3- to 6-membered heterocyclyl), wherein each R 4 is independently optionally substituted by halogen, oxo, —OR 19 , —NR 19 R 20 , or —C(O)R 19 ,

or two R 4 , when bound to the same carbon, are taken together with the carbon to which they are attached to form a C 3 -C 6 cycloalkyl or 3- to 6-membered heterocyclyl, each is optionally substituted by R 19 ; and

each R 17 , R 18 , R 19 , and R 20 is independently hydrogen, C 3 -C 6 cycloalkyl, 3-6 membered heterocyclyl or C 1 -C 6 alkyl, each of which is optionally substituted by halogen, oxo or —OH,

or R 17 and R 18 are taken together with the atom to which they attached to form a 3-6 membered heterocyclyl optionally substituted by halogen, oxo or —OH.

2 . The compound of claim 1 , or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of Formula (II):

3 . The compound of claim 1 , or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of Formula (III):

4 . The compound of claim 1 , or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is C 1 -C 6 alkyl.

5 . The compound of claim 4 , or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is isopropyl or ethyl.

6 . The compound of claim 1 , or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is C 3 -C 6 cycloalkyl.

7 . The compound of claim 6 , or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is cyclopropyl.

8 . The compound of claim 1 , or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is —(C 1 -C 3 alkylene)CF 3 .

9 . The compound of claim 8 , or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is —CH 2 CF 3 .

10 . The compound of claim 1 , or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 3 is selected from the group consisting of:

11 . The compound of claim 1 , or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing wherein R 3a is C 3 -C 6 cycloalkyl optionally substituted by C 1 -C 6 haloalkyl or —CN.

12 . The compound of claim 1 , or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 3a is C 1 -C 6 alkyl optionally substituted by halogen, —OH or —CN.

13 . The compound of claim 1 , or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 3a is selected from the group consisting of:

14 . The compound of claim 1 , or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 3b is halogen.

15 . The compound of claim 1 , or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 3b is —CN.

16 . The compound of claim 1 , or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 3 is selected from the group consisting of:

17 - 23 . (canceled)

24 . The compound of claim 1 , or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein ring A, ring B, R 1 , and R 4 are taken together to form a moiety selected from the group consisting of:

25 . A compound or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is selected from the group consisting of

26 . (canceled)

27 . A pharmaceutical composition comprising a compound of claim 1 , or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier.

28 . A method of treating a cancer in an individual in need thereof comprising administering to the individual a therapeutically effective amount of a compound of claim 1 , or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

29 - 41 . (canceled)